MarketCapExport financials
Collegium Pharmaceutical (COLL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Collegium Pharmaceutical Income Statement 2025-2011 | COLL
Brief overview of financial performance at Collegium Pharmaceutical
The figures are compared over a five-year interval. Collegium Pharmaceutical reported revenue of $310 million in 2020 and $205 million by 2025. The cumulative result was −33.7%, corresponding to roughly −7.9% per year. Revenue ended the period on a sustained downward trend.
At the gross-profit level, the result moved from $180 million to $128 million, a change of −28.6%. The cost base moved more slowly than the top line, which supported margins. At the margin level, the figure shifted from 58% to 62.5%. The business retained more gross profit from each unit of revenue.
Over the period, EBITDA shifted from 57.1 million dollars to 64.9 million dollars, a change of +13.7%. EBITDA grew faster than revenue, indicating positive operating leverage. EBITDA margin was 18.4% at the start and 31.6% at the end. The company improved its ability to convert sales into EBITDA.
The net result moved from $26.8 million to $63 million, or +135.5%. Net profitability strengthened faster than the top line.
Market capitalization changed from $831 million to $1.4 billion (+68.3%). The financial trend was stronger than the market valuation.
Conclusion
The results present an uneven picture without one dominant signal. The constructive conclusion rests on better sales economics, higher operating efficiency and improving net profitability. The weaker side of the profile includes limited revenue growth. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Collegium Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.4 B | 919 M | 1.1 B | 876 M | 624 M | 831 M | 669 M | 524 M | 733 M | 391 M | 231 M | - | - | - | - |
Shares |
31.7 M | 32.1 M | 33.7 M | 33.8 M | 34.9 M | 34.4 M | 33.5 M | 33 M | 30.3 M | 24.3 M | 13.5 M | - | - | - | - |
Historical Prices |
44.2 | 28.6 | 32.5 | 25.9 | 17.9 | 24.1 | 20.1 | 16 | 23.8 | 16.8 | 17 | - | - | - | - |
Net Income |
63 M | 69 M | 48 M | -25 M | 72 M | 26.8 M | -22.7 M | -39.1 M | -74.9 M | -94.2 M | -27.3 M | -17.9 M | -16.2 M | - | - |
Revenue |
205 M | 182 M | 567 M | 464 M | 277 M | 310 M | 297 M | 280 M | 28.5 M | 1.71 M | - | - | - | - | - |
Cost of Revenue |
77.1 M | 83.7 M | 241 M | 254 M | 126 M | 130 M | 194 M | 166 M | 2.6 M | 213 K | - | - | - | - | - |
Gross Profit |
128 M | 98.3 M | 326 M | 209 M | 151 M | 180 M | 103 M | 115 M | 25.9 M | 1.5 M | - | - | - | - | - |
Operating Income |
60.8 M | 38.1 M | 167 M | 33.3 M | 17.6 M | 56.2 M | -23.7 M | -20.7 M | -75.4 M | -94.1 M | -26.9 M | -17.7 M | -16 M | - | - |
Interest Expense |
- | - | 19.3 M | 20.6 M | 21 M | 28.9 M | 909 K | 20.1 M | 582 K | 94 K | 439 K | 252 K | -155 K | - | - |
EBITDA |
64.9 M | 42 M | 170 M | 36 M | 19.4 M | 57.1 M | -8.26 M | 90.2 M | -74.9 M | -93.4 M | -26.7 M | -17.5 M | -15.9 M | - | - |
Operating Expenses |
67.6 M | 60.2 M | 159 M | 176 M | 133 M | 124 M | 127 M | 135 M | 101 M | 95.6 M | 26.9 M | - | - | - | - |
General and Administrative Expenses |
67.6 M | 63.1 M | 159 M | 172 M | 119 M | 114 M | - | - | - | - | 18.9 M | 2.71 M | 1.88 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Collegium Pharmaceutical
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
31.7 M | 32.5 M | 32.1 M | 31.7 M | 31.6 M | 31.8 M | 31.8 M | 32.1 M | 32.3 M | 32.4 M | 32.3 M | 32.3 M | 33.7 M | 34.6 M | 34.3 M | 33.6 M | 34.1 M | 34 M | 33.7 M | 34.1 M | 35.4 M | 35.3 M | 35 M | 34.6 M | 34.5 M | 34.4 M | 34.1 M | 33.6 M | 33.5 M | 33.4 M | 33.3 M | 33.3 M | 33 M | 33 M | 32.9 M | 32.5 M | 29.8 M | 29.4 M | 29.4 M | 27.1 M | 23.5 M | 23.4 M | 23.1 M | 20.6 M | 20.5 M | 11.8 M | 1 M | 956 K | 941 K | 926 K | 913 K | 963 K | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
21.8 M | -15.1 M | 14.5 M | 17 M | 31.5 M | 12 M | 2.42 M | 12.5 M | 9.34 M | 19.6 M | 27.7 M | 31.9 M | 20.6 M | 13 M | -17.4 M | -7.2 M | 457 K | -5.19 M | -13.1 M | -25 M | 8.05 M | 72.8 M | 15.7 M | 6.96 M | 11.3 M | 8.06 M | 450 K | -2.2 M | -6.11 M | -4.71 M | -9.7 M | 9.09 M | -16.5 M | -13.1 M | -18.7 M | -17.4 M | -13.3 M | -21.1 M | -23.1 M | -27.6 M | -26.4 M | -24.5 M | -15.7 M | -9.52 M | -9.36 M | -5.32 M | 342 K | -3.47 M | -6.56 M | -4.12 M | -3.78 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
216 M | 200 M | 194 M | 205 M | 209 M | 188 M | 178 M | 182 M | 159 M | 145 M | 145 M | 150 M | 137 M | 136 M | 145 M | 130 M | 127 M | 124 M | 83.8 M | 27.4 M | 78.8 M | 82.9 M | 87.7 M | 76.3 M | 79.2 M | 78.1 M | 76.5 M | 74.2 M | 72.9 M | 75 M | 74.5 M | 73.4 M | 70.2 M | 73.1 M | 63.7 M | 10.8 M | 12 M | 3.56 M | 2.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
35.6 M | 26.6 M | 20.8 M | 21.6 M | 24.7 M | 24.1 M | 25 M | 28.2 M | 21.7 M | 20 M | 19 M | 20.6 M | 20.1 M | 24.3 M | 29.9 M | 37.6 M | 30.6 M | 33.7 M | 16.3 M | 11.9 M | 15.9 M | 15.9 M | 15.3 M | 15.2 M | 14.2 M | 12.9 M | 27.2 M | 45.4 M | 43.1 M | 45 M | 45.5 M | 29.7 M | 46 M | 46.8 M | 43.1 M | 1.09 M | 553 K | 577 K | 371 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
125 M | 110 M | 117 M | 128 M | 129 M | 108 M | 97.3 M | 98.3 M | 96.8 M | 90.8 M | 91.5 M | 94.6 M | 80.3 M | 73.8 M | 77.4 M | 49.8 M | 58.8 M | 52.4 M | 48.5 M | -1.33 M | 46.1 M | 50.2 M | 55.6 M | 44.3 M | 48.2 M | 48.4 M | 39 M | 25.1 M | 26.2 M | 26.4 M | 25.4 M | 43.7 M | 24.2 M | 26.2 M | 20.6 M | 9.7 M | 11.4 M | 2.98 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
28.7 M | 3.7 M | 30.9 M | 60.8 M | 62.1 M | 35.1 M | 21.7 M | 38.1 M | 34.8 M | 47.5 M | 49.5 M | 61.7 M | 45 M | 35.6 M | 24.6 M | 11.8 M | 20.5 M | 11.1 M | -10 M | -34.1 M | 14.1 M | 16.4 M | 21.2 M | 15 M | 19.6 M | 16.5 M | 5.06 M | -2.37 M | -6.38 M | -5.01 M | -9.99 M | 11 M | -11.2 M | -7.29 M | -13.2 M | -17.6 M | -13.4 M | -21.3 M | -23.2 M | -27.6 M | -26.4 M | -24.5 M | -15.6 M | -9.44 M | -9.26 M | -4.58 M | -3.63 M | -3.33 M | -6.5 M | -4.09 M | -3.74 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | 17.3 M | 19.3 M | 20.8 M | 21.9 M | 21.4 M | 20.6 M | 19 M | 17.8 M | 5.83 M | 4.76 M | 5.12 M | 5.42 M | 5.72 M | 7.74 M | 8.06 M | 8.26 M | 4.82 M | 211 K | 228 K | 236 K | 234 K | 2.4 M | 5.87 M | 6.16 M | 5.7 M | 180 K | 167 K | 137 K | 98 K | 20 K | -2 K | -46 K | -66 K | -89 K | -97 K | -99 K | -63 K | -142 K | -51 K | -29 K | -29 K | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
84.1 M | 66.7 M | 86.4 M | 116 M | 118 M | 90.6 M | 77.2 M | 93.6 M | 75.6 M | 82 M | 84 M | 96.2 M | 81.3 M | 73.1 M | 62.1 M | -79.5 M | 58 M | 48.6 M | 8.91 M | -17.3 M | 30.9 M | 33.2 M | 38 M | 31.8 M | 36.4 M | 33.3 M | 15.4 M | 1.32 M | -2.69 M | -1.32 M | -6.3 M | 26.5 M | 21.2 M | 25.1 M | 16.3 M | -17.6 M | -13.4 M | -21.2 M | -23 M | -27.4 M | -26.2 M | -24.4 M | -15.5 M | -9.4 M | -9.23 M | -4.53 M | -3.58 M | -3.33 M | -6.36 M | -3.99 M | -3.7 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
96.7 M | 107 M | 86.4 M | 67.6 M | 67.1 M | 73.3 M | 75.6 M | 60.2 M | 62 M | 43.3 M | 42 M | 32.9 M | 35.3 M | 38.2 M | 52.8 M | 38 M | 38.4 M | 41.3 M | 58.5 M | 32.8 M | 32 M | 33.8 M | 34.4 M | 29.3 M | 28.6 M | 31.8 M | 33.9 M | 27.5 M | 32.6 M | 31.4 M | 35.3 M | 32.7 M | 35.4 M | 33.5 M | 33.8 M | 27.3 M | 24.8 M | 24.2 M | 25 M | 28.9 M | 26.8 M | 24.5 M | 15.6 M | 9.44 M | 9.26 M | 4.58 M | 3.63 M | 3.33 M | 6.5 M | 4.09 M | 3.74 M | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
99.6 M | 107 M | 86.4 M | 67.6 M | 67.1 M | 73.6 M | 76.4 M | 63.1 M | 62 M | 43.3 M | 42 M | 32.9 M | 35.3 M | 38.2 M | 52.8 M | 38 M | 38.4 M | 41.3 M | 54.5 M | 26.6 M | 30.5 M | 30.4 M | 31.5 M | 26.8 M | 26.4 M | 29.3 M | 31.3 M | 25.1 M | 30.1 M | 28.9 M | 32.4 M | 30.5 M | 33.4 M | 31.3 M | 31.6 M | 25.1 M | 22.8 M | 22.1 M | 22.8 M | 25.4 M | 23.6 M | 20.2 M | 11.5 M | 7.9 M | 5.91 M | 2.93 M | 2.19 M | 1.02 M | 687 K | 523 K | 475 K | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Collegium Pharmaceutical (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Russia
Israel
Britain
Irlanda
France
Singapore
